This protocol is designed for a well-defined clinical presentation: myelodysplastic syndrome classified as lower-risk by IPSS-R (score up to 3.5), where the patient has moderate cytopaenias that are currently causing no symptoms.
For therapeutic purposes, the term “lower-risk” MDS applies to cases with IPSS-R up to 3.5 — covering very low- and low-risk, as well as part of the intermediate-risk IPSS-R group. In this scenario, the cytopaenias present are moderate in severity and remain asymptomatic, which is a key factor in determining the appropriate management path.
The evidence-based protocol for this presentation addresses the recommended management strategy for lower-risk MDS with moderate, asymptomatic cytopaenias. The full structured protocol details the approach relevant to this specific clinical situation.